55.14
+2.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cytokinetics
From its filings with the US Securities and Exchange Commission
Cytokinetics is based in South San Francisco, California. Its shares trade on Nasdaq under the ticker CYTK. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $88.0m and a net loss of $785.0m. At that date it held total assets of $1.42bn and shareholders' equity of −$659.6m.
Behind MYQORZO, we are making disciplined pipeline investments in investigational products that are at discovery, preclinical and clinical stages of research and development. All our research and development activities relate to the biology of muscle function and have evolved from our knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. As a leader in muscle biology and the mechanics of muscle performance, we are discovering and developing small molecule drug candidates specifically engineered to impact muscle function and contractility with the objective of building a sustainable specialty biopharmaceutical business.
Our specific focus on the biology of the cytoskeleton distinguishes us from other biopharmaceutical companies and potentially positions us to identify or discover and develop and commercialize novel therapeutics that may be useful for the treatment of severe diseases and medical conditions. We intend to leverage our experience in muscle contractility to expand our current pipeline and expect to identify additional potential drug candidates that may be suitable for clinical development and commercialization.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Apr 2004
- Employees
- 673
- Website
- cytokinetics.com ↗
- Head office
- 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. John HendersonIndependent Chairman of the Board$576,054
- Mr. Robert BlumPresident, Chief Executive Officer, Director, since 1998$14.4m
- Mr. Sung LeeChief Financial Officer, Executive Vice President$6.0m
- Mr. Andrew CallosExecutive Vice President, Chief Commercial Officer$4.4m
- Dr. Fady MalikExecutive Vice President - Research and Development$5.4m
- Ms. Muna BhanjiIndependent Director$524,804
- Mr. James DalyIndependent Director
- Dr. Robert HarringtonIndependent Director$518,137
- Dr. Edward KayeIndependent Director$532,721
- Mr. Robert LandryIndependent Director
- Ms. B. ParshallIndependent Director$548,971
- Dr. Wendell WierengaIndependent Director$545,637
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 65
- Social
- 99
- Governance
- 70
- Direct emissions (scope 1)
- 421 t
- Energy emissions (scope 2)
- 1,038 t
- Women in the workforce
- 48%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Research and Development: Cytokinetics Inc is known for its strong commitment to developing breakthrough therapies for patients with severe diseases.
- Robust Pipeline: The company has a diverse and promising pipeline of potential drug candidates, targeting various indications including cardiovascular and neuromuscular diseases.
- Strategic Partnerships: Cytokinetics has formed strategic collaborations with renowned pharmaceutical companies, enhancing its capabilities and resources in advancing drug development.
Weaknesses
- Limited Product Portfolio: The company heavily relies on the success of its drug candidates, with a limited number of approved products currently available.
- Dependency on Key Partnerships: Cytokinetics relies on collaborations with partners for funding, expertise, and market access, which introduces a level of dependency and risk.
- Regulatory Challenges: Like any pharmaceutical company, Cytokinetics faces regulatory hurdles and uncertainty, which can significantly impact the approval and market viability of its drug candidates.
Opportunities
- Growing Demand for Innovative Therapies: The increasing prevalence of cardiovascular and neuromuscular diseases presents an immense opportunity for Cytokinetics to address unmet medical needs with its R&D efforts.
- Expansion into New Geographies: The company can explore new markets and expand its global footprint, potentially reaching a larger patient population and generating additional revenue streams.
- Advancements in Technology: Emerging technologies like gene therapy and precision medicine provide opportunities for Cytokinetics to leverage scientific breakthroughs and develop novel treatment solutions.
Threats
- Intense Market Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies working on similar therapies, posing a threat to Cytokinetics' market share.
- Clinical Trial Setbacks: The failure of clinical trials or unexpected safety concerns can result in setbacks and delays, impacting both the company's reputation and financial performance.
- Pricing and Reimbursement Pressures: Cytokinetics may face challenges in pricing its products competitively and navigating reimbursement processes, which can affect market penetration and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.